{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:11:30Z","timestamp":1791558690304,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clon.2023.11.030","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T23:43:31Z","timestamp":1699659811000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study"],"prefix":"10.1016","volume":"36","author":[{"given":"J.","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1427-1549","authenticated-orcid":false,"given":"X.-H.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2023.11.030_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2023.11.030_bib2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2023.11.030_bib3","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/2159-8290.CD-20-1863","article-title":"Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation","volume":"11","author":"Quintanal-Villalonga","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clon.2023.11.030_bib4","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer","volume":"59","author":"He","year":"2021","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.semcancer.2022.03.006","article-title":"Small cell lung cancer transformation: from pathogenesis to treatment","volume":"86","author":"Yin","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clon.2023.11.030_bib6","article-title":"Genomic and transcriptomic analysis of neuroendocrine transformation in ALK-rearranged lung adenocarcinoma after treatments with sequential ALK inhibitors: a brief report","volume":"3","author":"Huang","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.clon.2023.11.030_bib7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clon.2023.11.030_bib10","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target\u00a0alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2023.11.030_bib11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2018.08.2028","article-title":"A\u00a0brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics","volume":"14","author":"Ferrer","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2021.03.006","article-title":"Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: a multicenter retrospective study","volume":"155","author":"Wang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2023.11.030_bib14","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.19.03123","article-title":"Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review","volume":"38","author":"Piper-Vallillo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib15","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/1759-7714.14144","article-title":"Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.clon.2023.11.030_bib16","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.jtho.2021.01.259","article-title":"Chemotherapy plus EGFR TKIs or bevacizumab versus chemotherapy alone in SCLC-transformed EGFR-mutant lung adenocarcinoma","volume":"16","author":"Zhang","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clon.2023.11.030_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","article-title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial","volume":"31","author":"Mansfield","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2022.11.016","article-title":"A\u00a0potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival","volume":"175","author":"Zhang","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2023.11.030_bib21","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1200\/JCO.2021.39.15_suppl.2566","article-title":"Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: a single-arm, multicenter, phase 2 study","volume":"39","author":"Qin","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib22","series-title":"The NDA of Henlius novel anti-PD-1 mAb serplulimab for first-line treatment of sqNSCLC accepted by China's NMPA, phase 3 MRCT met its primary endpoint","author":"Shanghai Henlius Biotech","year":"2021"},{"key":"10.1016\/j.clon.2023.11.030_bib23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2023.11.030_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12935-022-02588-w","article-title":"Genomic and immunological profiles of small-cell lung cancer between East Asians and Caucasian","volume":"22","author":"Lin","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.clon.2023.11.030_bib25","first-page":"153","article-title":"Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas","volume":"1","author":"Zhong","year":"2021","journal-title":"J\u00a0Natl Cancer Cent"},{"key":"10.1016\/j.clon.2023.11.030_bib27","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S1556-0864(23)00286-1","article-title":"32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI","volume":"18","author":"Wang","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib28","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/ncomms7377","article-title":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer","volume":"6","author":"Niederst","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.clon.2023.11.030_bib29","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","article-title":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","volume":"35","author":"Lee","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.11.030_bib30","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/s41467-021-22057-8","article-title":"Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers","volume":"12","author":"Vaclova","year":"2021","journal-title":"Nat Commun"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523004454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523004454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:53:13Z","timestamp":1760543593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655523004454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0936655523004454"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2023.11.030","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2023.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}